Spironolactone inhibits the mineralocorticoid effect of 11-OP
| Steroid | +SPO (100 μg) | Urinary Electrolyte (Steroid/ADX Ratio) | ||
|---|---|---|---|---|
| Na+ | K+ | Na+/K+ | ||
| 1 μg of ALDO | No | 0.195 ± 0.024 | 1.595 ± 0.061 | 0.132 ± 0.046 |
| 1 μg of ALDO | Yes | 0.958 ± 0.088 | 1.014 ± 0.114 | 0.957 ± 0.094 |
| 100 μg of 11-OP | No | 0.231 ± 0.017 | 1.449 ± 0.152 | 0.161 ± 0.089 |
| 100 μg of 11-OP | Yes | 0.924 ± 0.091 | 1.081 ± 0.047 | 0.857 ± 0.060 |
| 1 μg of ALDO + 100 μg of 11-OP | No | 0.178 ± 0.024 | 1.634 ± 0.551 | 0.110 ± 0.046 |
| 1 μg of ALDO + 100 μg of 11-OP | Yes | 0.935 ± 0.132 | 1.154 ± 0.077 | 0.819 ± 0.110 |
| 0.06 μg of ALDO | No | 0.568 ± 0.055 | 1.200 ± 0.209 | 0.479 ± 0.122 |
| 0.6 ng of 11-OP | No | 0.944 ± 0.072 | 0.973 ± 0.098 | 1.040 ± 0.147 |
| 0.06 μg of ALDO + 0.6 ng of 11-OP | No | 0.171 ± 0.075 | 1.560 ± 0.124 | 0.249 ± 0.150 |
| 0.06 μg of ALDO + 0.6 ng of 11-OP | Yes | 0.860 ± 0.132 | 1.020 ± 0.091 | 0.870 ± 0.126 |
ADX male rats were injected with the indicated doses (expressed per 100 g of body weight) of ALDO, 11-OP, or both steroids together. To inhibit the mineralocorticoid effect, 100 μg of SPO was also coinjected with the agonist. After 3 h, urine samples were collected by bladder puncture and both natriuresis and kaliuresis were measured. Results represent the mean ± S.E. (9 rats/group). The inhibitory effect observed for SPO is statistically different for all treatments at P < .001.